Annexon，Inc。
About Annexon，Inc。
91articles about Annexon，Inc。
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule5635（c）（4）-May162024 5/16/2024 Annexon，Inc.announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan。 -
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones 5/13/2024 Annexon，Inc.，abiopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body，brain，and eye，highlighted portfolio progress and reported first quarter2024financial sults。 -
America2024 Health Care Conference 5/9/2024 Annexon，Inc.announced that Douglas Love，president and chief executive officer，will present at the Bank of America Health Care Conference on Tuesday，May142024at8:40a.m.PT。 -
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule5635（c）（4）-April 162024 4/16/2024 Annexon，Inc.announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan。 -
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule5635（c）（4）-March 182024 3/18/2024 Annexon，Inc.announced that it has granted inducement to anew non-executive employee under the terms of the 2022 Employment Inducement Award Plan。 -
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule5635（c）（4）-February202024 2/20/2024 Annexon，Inc.announced that it has granted inducement to anew non-executive employee under the terms of the 2022 Employment Inducement Award Plan。 -
From ALS to depression to Huntington’s disease，many neuroscience-focused companies are anticipating key data over the next few months。 -
Annexon Outlines2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune，Opthalmic and Neurodegenerative Diseases 1/8/2024 Annexon，Inc.outlined its strategic priorities for 2024 with late-stage clinical milestones，including ANX005 for Guillain-Barrésyndrome，ANX007 for geographic atrophy and its first-in-kind oral small molecule complement inhibitor，ANX1502，for arange of autoimne indications。 -
Annexon Biosciences to Present at the 42nd Annual J.P.Morgan Healthcare Conference 12/27/2023 Annexon，Inc.announced that Douglas Love，president and chief executive officer，will present at the 42nd Annual J.P.Morgan Healthcare Conference on Wednesday，January，2024at2:15p.m.PT in San Francisco。 -
Annexon Announces Pricing of$125.0 Million Underwritten Public Offering of Common Stock 12/20/2023 Annexon，Inc.announced the pricing of an underwritten public offering of 25035000 shares of its common stock and pre-funded warrants to purchase18379861shares of common stock。 -
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule5635（c）（4）-December 182023 12/18/2023 Annexon，Inc.announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan。 -
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference 11/22/2023 Annexon，Inc.announced that Douglas Love，president and chief executive officer，will participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday，November292023at2:10p.m.ET in Miami。 -
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results 11/13/2023 Annexon，Inc.，aclinical-stage biopharmaceutical company developing anew class of complement-based medicines forpeople living with devastating inflammatory-related diseases，highlighted portfolio progress and reported third quarter2023financial results。 -
Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference 11/9/2023 Annexon，Inc.announced that Douglas Love，president and chief executive officer，will participate in a fireside chat during the 2023Jefferies London Healthcare Conference on Wednesday，November152023at10:30a.m.GMT in London。 -
Geographic Atrophy of Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment 10/24/2023 Annexon，Inc.announced that the European Medicines Agency has granted Priority Medicine designation to ANX007 for the treatment of geographic atrophy secondary to age-related macular degeneration。 -
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule5635（c）（4）-October 182023 10/18/2023 Annexon，Inc.announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan。 -
ANX005 Pivotal Program in Guillain-BarréSyndrome（GBS） 10/10/2023 Annexon，Inc.announced that the European Medicines Agency granted orphan drug designation to ANX005 for the treatment of Guillain-BarréSyndrome。 -
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference 9/19/2023 Annexon，Inc.announced that Douglas Love，president and chief executive officer，will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday，September262023 at8:10a.m.ET in NYC。 -
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule5635（c）（4）-September18203 9/18/2023 Annexon，Inc.announced that it has granted inducement to anew non-executive employee under the terms of the 2022 Employment Inducement Award Plan。 -
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results 8/7/2023 Annexon，Inc.，aclinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune，neurodegenerative and ophthalmic disorders，highlighted recent progress its business and portfolsec of complement aptheries and retunes lts。